Autolus therapeutics to present clinical data updates at the american society of hematology (ash) annual meeting 2025

London and gaithersburg, md., nov. 03, 2025 (globe newswire) -- autolus therapeutics plc (nasdaq: autl), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed t cell therapies, announces the online publication of five abstracts submitted to the american society of hematology (ash) annual meeting, to be held december 6-9, 2025, in orlando, florida.
ASH Ratings Summary
ASH Quant Ranking